mdlinx mdlinx
Latest (77) Full Text Articles (1570) Focus on Hepatitis Article Summary

Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study Full Text
World Journal of Gastroenterology,  Clinical Article

Tack GJ et al. – The study aims to assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN–PEP) to mitigate the immunogenic effects of gluten in celiac patients. AN–PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN–PEP.

Methods

  • Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included.
  • In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase).
  • After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase).
  • Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology.
  • Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase.
  • Duodenal biopsies were collected after the safety phase and after the efficacy phase.
  • A change in histological evaluation according to the modified Marsh classification was the primary endpoint.

Results

  • In total, 16 adults were enrolled in the study.
  • No serious adverse events occurred during the trial and no patients withdrew during the trial.
  • The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated.
  • In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed.
  • During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers.
  • The IgA-EM concentrations remained negative in both groups.
  • Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP.
  • Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP.
  • Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo.
  • In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2013

1 Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease Alimentary Pharmacology and Therapeutics, February 28, 2014    Clinical Article

2 Fungal microbiota and digestive diseases Alimentary Pharmacology and Therapeutics, March 5, 2014    Review Article

3 Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy. A case-control study Journal of Gastroenterology and Hepatology, March 27, 2014    Clinical Article

4 Once versus three times daily dosing of oral budesonide for active Crohns disease: A double-blind, double-dummy, randomised trial Journal of Crohn's and Colitis, February 21, 2014    Clinical Article

5 Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: An open-label multicentre study Alimentary Pharmacology and Therapeutics, March 25, 2014    Clinical Article

6 Low adherence to Helicobacter pylori testing in hospitalized patients with bleeding peptic ulcer disease Helicobacter, March 21, 2014    Clinical Article

7 Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial Neurogastroenterology & Motility, February 10, 2014    Clinical Article

8 Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial Complementary Therapies in Medicine, March 4, 2014    Clinical Article

9 Role of vitamin D derivatives in intestinal tissue of patients with inflammatory bowel diseases Journal of Crohn's and Colitis, March 17, 2014    Clinical Article

10 Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation Clinical Gastroenterology and Hepatology , January 17, 2014    Clinical Article

11 Calcium intake and colorectal cancer risk: Dose-response meta-analysis of prospective observational studies International Journal of Cancer, March 14, 2014    Evidence Based Medicine    Clinical Article

12 Disease course and surgery rates in inflammatory bowel disease: A population-based, 7-year follow-up study in the era of immunomodulating therapy The American Journal of Gastroenterology, March 19, 2014    Clinical Article

13 A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease Journal of Crohn's and Colitis, March 5, 2014    Clinical Article

14 The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis Alimentary Pharmacology and Therapeutics, March 12, 2014    Clinical Article

15 Use of proton pump inhibitors and subsequent risk of celiac disease Digestive and Liver Diseases, September 20, 2013    Clinical Article

16 Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy Gastroenterology, February 28, 2014    Clinical Article

17 Iron treatment and inflammatory bowel disease Journal of Crohn's and Colitis, February 11, 2014    Clinical Article

18 Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease Clinical Gastroenterology and Hepatology , March 4, 2014    Clinical Article

19 Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C Gastroenterology, February 28, 2014    Clinical Article

20 Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: Changes following treatment with immunomodulators and/or anti-TNF antibodies Journal of Crohn's and Colitis, March 24, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close